Form 4: Supernus Director Exercises Stock Options
Insider Transaction Report
Supernus Pharmaceuticals Director Frederick M. Hudson exercised options to acquire 15,000 shares of common stock.
Summary
- Frederick M. Hudson, a Director of Supernus Pharmaceuticals, Inc. (SUPN), acquired 15,000 shares of common stock.
- The transaction occurred on January 9, 2026, through the exercise of a Director Stock Option.
- The exercise price for the common stock was $12.98 per share.
- Following this transaction, Frederick M. Hudson directly beneficially owns 61,307 shares of common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 6
Explanation: A director's exercise of stock options and increase in direct ownership is generally viewed as a neutral to slightly positive signal of confidence in the company.
Positives
- A director increased their direct beneficial ownership of common stock, which can be interpreted as a sign of confidence in the company's future prospects.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged transaction and potentially reducing concerns about opportunistic insider trading.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was conducted under a Rule 10b5-1(c) plan, which is a pre-arranged trading plan designed to comply with insider trading laws. | 01/09/2026 | Indicates a structured approach to insider equity transactions, potentially enhancing transparency and reducing perceptions of opportunistic trading. |
Related Party Transactions
- Director Frederick M. Hudson acquired shares from Supernus Pharmaceuticals through the exercise of stock options, which is a related party transaction.
Stakeholder Impact
- Shareholders: The increase in direct beneficial ownership by a director may be viewed as a minor positive signal of management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/01/2017 | Director Stock Option became exercisable |
| 01/09/2026 | Transaction date for the exercise of stock options |
| 01/12/2026 | Date the Form 4 filing was signed |
| 03/01/2026 | Expiration date of the Director Stock Option |
Keywords
Supernus Pharmaceuticals, SUPN, Form 4, Insider Transaction, Stock Option Exercise, Director Stock, Equity Acquisition, Frederick M. Hudson, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.